ArticleAdvances in radiation oncology
Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Trial
- Evolving role of radiation therapy in advanced/metastatic intrahepatic cholangiocarcinoma.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Ultra- and Moderately Hypofractionated Radiotherapy for Inoperable Cholangiocarcinoma: A Single-Institution Retrospective Analysis.Current oncology (Toronto, Ont.) · 2025Article
- Definitive radiotherapy for unresectable extrahepatic cholangiocarcinoma: is it time for an update?Radiation oncology journal · 2025Article
- Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study.Cancer research and treatment · 2024Article
- The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review.Cancers · 2024Review
- Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.Life (Basel, Switzerland) · 2024Review
- SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know.Seminars in interventional radiology · 2024Review
- Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?Cancers · 2023Review
- Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients' registration database, Proton-Net.Clinical and translational radiation oncology · 2023Article
- Review
- Article
- Stereotactic radiotherapy for intrahepatic cholangiocarcinoma.World journal of gastrointestinal oncology · 2022Review
- Article
- Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis.Liver cancer · 2021Article
- Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review.Molecular and clinical oncology · 2021Article
- Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer.Journal of gastrointestinal oncology · 2020Article
- Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this.World journal of hepatology · 2020Article
- Clinical Outcomes of Patients With Unresectable Primary Liver Cancer Treated With Yttrium-90 Radioembolization With an Escalated Dose.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review our institutional experience of treating cholangiocarcinoma using stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: A total of 40 patients with intrahepatic (
resultsThe median follow-up time was 18 months. The 1-year incidence of local in-field, local out-of-field, regional, and distant failure was 8%, 23%, 13%, and 22%, respectively. Median OS was 23 months and 1- and 2-year OS rates were 69% and 39%, respectively. Patients with perihilar tumors had a 1-year incidence of regional failure of 24% and worse OS (
conclusionsIn this series of cholangiocarcinoma patients treated with definitive SBRT, patterns of failure reveal that regional failures are not insignificant, particularly for perihilar tumors. Elective nodal irradiation of regional lymphatics should be considered when using SBRT. A prospective study of elective nodal irradiation in patients with perihilar tumors would further clarify whether this approach improves outcomes without increasing hepatobiliary toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.